Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Immune checkpoint inhibitors in melanoma
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
Immune-related adverse events and the balancing act of immunotherapy
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double …
Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
K Chamoto, T Yaguchi, M Tajima, T Honjo - Nature Reviews …, 2023 - nature.com
PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
RJ Sullivan, JS Weber - Nature reviews Drug discovery, 2022 - nature.com
The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
Germline variants associated with toxicity to immune checkpoint blockade
Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …
immune-related adverse events (irAEs). Although germline causes for irAEs have been …
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw… - Nature medicine, 2021 - nature.com
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …
Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia
M Ferrer, N Mourikis, EE Davidson, SO Kleeman… - Cell metabolism, 2023 - cell.com
Glucose dependency of cancer cells can be targeted with a high-fat, low-carbohydrate
ketogenic diet (KD). However, in IL-6-producing cancers, suppression of the hepatic …
ketogenic diet (KD). However, in IL-6-producing cancers, suppression of the hepatic …
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors–a systematic review and meta-analysis
S Hussaini, R Chehade, RG Boldt, J Raphael… - Cancer Treatment …, 2021 - Elsevier
Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …
many tumor sites. The aim of this study is to systematically review the literature to determine …